Journal article

Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?

Hui Yi Chew, Victor Chan, Fiona Simpson, Riccardo Dolcetti

CANCERS | MDPI | Published : 2020


Sarcomas are a rare type of a heterogeneous group of tumours arising from mesenchymal cells that form connective tissues. Surgery is the most common treatment for these tumours, but additional neoadjuvant or adjuvant chemotherapy or radiation therapies may be necessary. Unfortunately, a significant proportion of patients treated with conventional therapies will develop metastatic disease that is resistant to therapies. Currently, there is an urgent need to develop more effective and durable therapies for the treatment of sarcomas. In recent years immunotherapies have revolutionised the treatment of a variety of cancers by restoring patient anti-tumour immune responses or through the adoptive..

View full abstract


Awarded by National Breast Cancer Foundation (NBCF) of Australia

Awarded by Cancer Council Queensland

Funding Acknowledgements

This work was supported by grants from National Breast Cancer Foundation (NBCF) of Australia (IIRS-18-047 and IIRS-20-073) and Cancer Council Queensland (1145758 and 1165064).